Return to the full list of Biomarkers
Metabolic Hyperspectral Retinal Camera (MHRC)
Method of Measurement (Pre-analytical Tools)
Optical
Biomarker Measured
Amyloid
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results
Evaluate the Metabolic Hyperspectral Retinal Camera (MHRC), a novel medical instrument from Optina Diagnostics, for the detection of beta-amyloid plaques, a hallmark of Alzheimer's disease (AD), in the retina.
Target Population/ Population Being Studied
Patients with AD or MCI and healthy controls
Length of Current Trial
21 days
Number of Trial Participants
50
Estimated Trial Completion
September 2020
What is Required from Patients
noninvasive eye imaging
What is Required from the Health System
Metabolic Hyperspectral Retinal Camera, technicians
Sponsor
Optina Diagnostics; McGill University; Polytechnique Montreal; Sunnybrook Health Sciences Centre
“Retinal Metabolic Imaging of Alzheimer Patient.” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03420807?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=11&rank=95